Language

Q1 2017 OncoMed Pharmaceuticals Inc Earnings Call

8/5/2017 8:30

Conference Call OncoMed Pharmaceuticals Inc

OncoMed Pharmaceuticals Inc Conference call will be held on May 8, 2017. During the earnings conference call's session OncoMed Pharmaceuticals Inc will provide updated information and financial status.

Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period

In order to join the earnings online meeting, contact OncoMed Pharmaceuticals Inc for the information on connecting using web conferencing or bridge number and PIN code

OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics. We have seven internally discovered product candidates in clinical development and have treated over 1000 patients across all of our clinical trials. We have two biologic product candidates in the immuno-oncology area advancing toward Investigational New Drug, or IND, application filings with the U.S. Food and Drug Administration, or FDA and we plan to file at least one of these by the end of 2016. We are also pursuing discovery of additional novel anti-CSC and immuno-oncology product candidates. The following summarizes the status of our product candidates and preclinical programs, each of which will be described and discussed in further detail below under "--Our Product Candidates and Preclinical Programs." * Demcizumab (Anti-DLL4, OMP-21M18).